Peak: A randomized, Multicenter Phase II study of panitumumab plus modified fluorouracil, leucovorin, and Oxaliplatin (MFOLFOX6) or bevacizumab plus MFOLFOX6 in patients with previously untreated, unresectable, wild-type kras exon 2 metastatic colorectal cancer - Schwartzberg, L S; Rivera, F; Karthaus, M; Fasola, G; Canon, J L; Hecht, J R; Yu, H; Oliner, K S; Go, W Y (Journal of Clinical Oncology, 2014)